Volume 16, Number 11—November 2010
CME ACTIVITY - Research
Enhanced Surveillance of Coccidioidomycosis, Arizona, USA, 2007–2008
Table 2
Characteristic | No. (%) |
---|---|
Coexisting condition | |
Heart disease | 62 (13) |
Lung disease | 90 (18) |
Asthma requiring inhaler | 47 (10) |
COPD or emphysema | 27 (6) |
Other | 29 (6) |
Malignancy | 70 (14) |
Transplant | 11 (2) |
HIV | 9 (2) |
Diabetes mellitus | 72 (15) |
None |
164 (33) |
Immunosuppression† |
97 (20) |
Smoker | |
Active | 76 (15) |
Past | 203 (41) |
Never | 202 (41) |
Unknown |
12 (2) |
Site of infection, n = 282 | |
Primary pulmonary‡ | 240 (85) |
Disseminated§ | 42 (15) |
*N = 493. COPD, chronic obstructive pulmonary disease.
†Immunosuppression is defined as having HIV/AIDS, a solid-organ transplant, or a bone marrow transplant or taking immunosuppressive medications. Immunosuppressive medications refer to medications that suppress the immune system and include chemotherapy medications such as steroids, prednisone, dexamethasone, infliximab, or interferon, as self-reported by patients.
‡Primary pulmonary infection is defined as the lungs being the only site of infection, as self-reported by patients.
§Disseminated infection is defined as infection spread to other parts of the body, including the central nervous system, bone, and entire body, as self-reported by patients.
Page created: September 07, 2011
Page updated: September 07, 2011
Page reviewed: September 07, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.